OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
RDGT
Ridgetech Inc.
There isn't enough reported data to score RDGT yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
RDGT Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Strong |
RDGT's profitability and balance sheet are currently healthy. There isn't enough data to rate its revenue and cash flow.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
RDGT PE Valuation
RDGT has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
RDGT Forward outlook
There aren't enough analyst estimates for RDGT to show an outlook.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the stronger earnings trend. Trailing diluted EPS is up 147% for OSCR versus RDGT down 100%.
RDGT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2021 | -$1,098,000.00 | -$132,750.00 |
| Q4 2020 | -$1,559,250.00 | -1185% |
| Q3 2020 | -$641,250.00 | -$353,025.00 |
| Q2 2020 | -$641,250.00 | -$245,025.00 |
| Q1 2020 | -$965,250.00 | -$839,025.00 |
| Q4 2019 | $143,775.00 | +$3,460,500.00 |
| Q3 2019 | -$288,225.00 | +$3,136,500.00 |
| Q2 2019 | -$396,225.00 | +$2,974,500.00 |
RDGT has returned to profit: it earned $276.00 per share over the past year, after losing money the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the stronger quarterly revenue trend. Revenue is up 72% for OSCR versus down 8.7% for RDGT.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
RDGT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $69.4M | -42% |
| Q3 2025 | $62.8M | -12% |
| Q1 2025 | $120M | +58% |
| Q3 2024 | $71.2M | -9.4% |
| Q1 2024 | $76M | -49% |
| Q1 2023 | $148.8M | -9.5% |
| Q1 2022 | $164.4M | +360% |
| Q1 2021 | $35.7M | +18% |
RDGT's revenue has slid since its 2022 peak: $69M last quarter, down 8.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q1 2026 | -2.6% | +2.4 points |
| Q3 2025 | -0.1% | -0.5 points |
| Q1 2025 | -0.9% | +13 points |
| Q3 2024 | -3.1% | -1.5 points |
| Q1 2024 | -5% | -3.5 points |
| Q3 2023 | 0.3% | +18 points |
| Q1 2023 | -14% | -9.1 points |
| Q1 2022 | -1.6% | -0.3 points |
RDGT's operating margin was −2.6% last quarter, up 2.4 points from the same quarter a year ago.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with RDGT at down 77%.
RDGT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q1 2025 | $1.1M | +$5.3M |
| Q3 2024 | -$10.1M | -1517% |
| Q1 2024 | -$4.2M | -$797.7K |
| Q1 2023 | -$3.4M | +$2.1M |
| Q1 2022 | -$5.5M | -145% |
| Q1 2021 | $12.1M | +219% |
| Q4 2020 | -$12.1M | +$387.3K |
| Q3 2020 | $5M | -44% |
RDGT's free cash flow was −$13M over the past year, against −$9M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over RDGT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
RDGT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +5.6% | +2.1K shares |
| 1 year | +1048% | +35.6K shares |
| 3 years | +650450% | +39K shares |
| 5 years | +780560% | +39K shares |
| Available history | +1301000% | +39K shares |
RDGT has 39,033 diluted shares, up 1048% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
| Q3 2019 | — |
| Q2 2019 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
RDGT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2025 | -23.5x | Net Cash |
| Q1 2019 | 20.8x | High |
| Q3 2016 | 3.2x | Elevated |
RDGT has more cash than debt.
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
RDGT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.8 | Neutral |
| Stochastic | 28.7 | Neutral |
RDGT's weekly RSI is 35 (neutral) and its Stochastic is 29 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
RDGT PE vs Healthcare Sector
| Metric | RDGT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
RDGT has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over RDGT on trend strength, trading above more of its moving averages.
RDGT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.91 | 22% above |
| 20 week MA | $0.99 | 12% above |
| 50 week MA | $122.2 | 99% below |
| 100 week MA | $171.8 | 99% below |
| 200 week MA | $1,289.0 | 100% below |
RDGT has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 100% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over RDGT on returns for 2026, with the stronger performance.
RDGT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $66,240.0 | $37,080.0 | -44% |
| 2021 | $37,080.0 | $14,047.6 | -62% |
| 2022 | $14,047.6 | $11,850.0 | -16% |
| 2023 | $11,850.0 | $666.0 | -94% |
| 2024 | $666.0 | $271.5 | -59% |
| 2025 | $271.5 | $483.0 | +78% |
| 2026 YTD | $483.0 | $1.11 | -100% |
RDGT has finished lower in five of the last six years. It's down 100% so far in 2026.